https://www.thepeptidenewsroom.com/systematic-review-finds-two-oral-glp-1-pills-matched-on-efficacy-but-split-on-to/ The Peptide Newsroom en 2026-09-22 Systematic Review Finds Two Oral GLP-1 Pills Matched on Efficacy but Split on Tolerability https://www.thepeptidenewsroom.com/semaglutide-carried-the-highest-optic-neuropathy-signal-among-glp-1-drugs-but-th/ The Peptide Newsroom en 2026-09-22 Semaglutide Carried the Highest Optic Neuropathy Signal Among GLP-1 Drugs, But the Data Are Indirect https://www.thepeptidenewsroom.com/nad-sells-as-anti-aging-science-but-the-published-evidence-is-still-thin/ The Peptide Newsroom en 2026-09-22 NAD+ Sells as Anti-Aging Science, But the Published Evidence Is Still Thin https://www.thepeptidenewsroom.com/martha-stewarts-elm-launches-a-45-peptide-lip-serum-but-its-study-is-a-perceptio/ The Peptide Newsroom en 2026-09-22 Martha Stewart's Elm Launches a $45 Peptide Lip Serum, But Its Study Is a Perception Test https://www.thepeptidenewsroom.com/tirzepatide-linked-to-fewer-oral-and-periodontal-events-than-glp-1-drugs-in-glob/ The Peptide Newsroom en 2026-09-21 Tirzepatide Linked to Fewer Oral and Periodontal Events Than GLP-1 Drugs in Global Cohort https://www.thepeptidenewsroom.com/allergan-aesthetics-reports-skin-gains-in-glp-1-patients-but-the-studies-are-tin/ The Peptide Newsroom en 2026-09-21 Allergan Aesthetics Reports Skin Gains in GLP-1 Patients, But the Studies Are Tiny